Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;84(2):248-288.
doi: 10.1016/j.jinf.2021.08.033. Epub 2021 Aug 23.

Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance

Aurélie Guigon  1 , Emmanuel Faure  2 , Chloé Lemaire  1 , Marie-Charlotte Chopin  2 , Claire Tinez  1 , Ady Assaf  2 , Mouna Lazrek  1 , Didier Hober  1 , Laurence Bocket  1 , Ilka Engelmann  1 , Enagnon Kazali Alidjinou  3
Affiliations

Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance

Aurélie Guigon et al. J Infect. 2022 Feb.
No abstract available

PubMed Disclaimer

References

    1. Gottlieb Robert L., Ajay N., Peter C., Joseph B., Barry H., Jason M., et al. Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial. JAMA. 2021;325(7):632–644. doi: 10.1001/jama.2021.0202. - DOI - PMC - PubMed
    1. EMA. Assessment report. Eli Lilly and Company Limited use of bamlanivimab and etesevimab for the treatment of COVID-19 2021 https://www.ema.europa.eu/en/documents/referral/eli-lilly-company-limite.... Accessed August 2nd, 2021.
    1. Daniele F., Fabrizio M. Neutralising antibody escape of SARS-CoV-2 spike protein: risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev Med Virol. 2021 doi: 10.1002/rmv.2231. rmv.2231. - DOI - PMC - PubMed
    1. FDA. Fact sheet for health care providers emergency use authorization (EUA) of Bamlanivimab and Etesevimab 2021 https://www.fda.gov/media/145802/download. Accessed August 2nd, 2021.
    1. Starr Tyler N., Greaney Allison J., Dingens Adam S., Bloom Jesse D. Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016. Cell Rep Med. 2021;2(4) doi: 10.1016/j.xcrm.2021.100255. - DOI - PMC - PubMed

MeSH terms